QIAGEN and Protedyne Enter Collaboration to Develop Nucleic Acid Purification Solution for Ultra High-Throughput Molecular Diagnostics Customers
Venlo, The Netherlands and Windsor, CT, June 14, 2004 - QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA), a leading supplier of products and technologies for nucleic acid separation, purification and handling, and Protedyne Corporation, a premier supplier of industrial robotics for research, drug discovery and testing laboratories, today announced that they have entered into a collaboration to develop a fully automated ultra high-throughput sample preparation system for molecular diagnostic customers. The collaboration is aimed at developing optimized ultra high-throughput nucleic acid purification procedures on Protedyne's BioCube Systems.
QIAGEN's proprietary nucleic acid sample preparation and handling technologies provide the highest reliability and efficiency in all preanalytical sample preparation steps, from sample collection to separation, purification and handling of DNA and RNA in molecular diagnostics. Protedyne Corporation brings industrial laboratory automation solutions to today's progressive biotechnology, diagnostics, and pharmaceutical companies.
Optimized protocols for ultra high-throughput diagnostic sample preparation which result from this collaboration will be described in technical notes to be made available by both companies.
"We are very pleased that Protedyne and QIAGEN have entered into a partnership," said Dr. Frank Krieg-Schneider, Director Strategic Alliances at QIAGEN. "The combination of Protedyne's ultra high-throughput automation systems with QIAGEN's preanalytical sample preparation technologies strengthens QIAGEN's already broad portfolio of automated sample preparation solutions for molecular diagnostics and clinical research in the fields of ultra high-throughput applications. We strongly believe that QIAGEN's technology and market leadership in preanalytical sample preparation is adding substantial value to the molecular diagnostics markets and will boost the development of standardized and highly efficient solutions in these emerging and rapidly growing markets."
"We are excited to extend our diagnostics application portfolio through this partnership with QIAGEN. The combination of proven purification chemistries and robust automation will greatly benefit ultra high throughput customers," says Greg Endress, Protedyne's Chief Scientific Officer. "Together they enable the quick processing of patient samples while maintaining integrity. It also permits the rapid movement of samples into a number of molecular diagnostic tests."
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com .
Protedyne's unique approach combines scientific and automation expertise with industrial-quality automation and sophisticated data management. The foundation of the company is the BioCubeTM System, which brings advanced industrial automation capabilities into life science and diagnostic laboratories in a fast, flexible, and reliable package. Protedyne is headquartered in Windsor, Connecticut. For more information, call (860) 683-1860 in North America or visit Protedyne on the web at http://www.protedyne.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
Kontakt:IR QIAGEN N.V.
Tel.: +49 2103 29 11710
Fax +49 2103 29 21710
Email firstname.lastname@example.org f